RxDoctor Payments Data

Heidi Smith

Adult Health · Mason City, IANPI 1588289672

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 41.5% of the total. Reporting peaked in 2023 at $151 and has fallen 83.0% since, to $26 in 2025. That places this record below the midpoint for adult health clinicians in IA, where the typical reported total is $180.

$206in general payments, 2019–2025

Across 12 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$85
  • Novartis$33
  • Novocure Inc.$26
  • Seagen Inc.$16
  • Merck$16
  • Incyte Corporation$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$206 in reported general payments places this provider in the 50th percentile of 77 adult health providers in Iowa.

See all adult health providers in Iowa

Medicare billing

Part B allowed, 2024
$47,046
Medicare patients
296
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib33$496,379
TukysaTucatinib18$464,053
ImbruvicaIbrutinib28$397,352
CabometyxCabozantinib S-Malate13$339,250
XtandiEnzalutamide20$273,426
RevlimidLenalidomide12$186,088
CalquenceAcalabrutinib Maleate12$184,786
ErleadaApalutamide12$165,765
EliquisApixaban25$17,108
Abiraterone Acetate19$16,100
Imatinib Mesylate22$4,039
Hydroxyurea68$1,096
Ursodiol12$754
Anastrozole16$409
Gabapentin27$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Seagen Inc.Tukysa$16$464,05318 claims
Johnson & JohnsonErleada$85$165,76512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 77 adult health providers in Iowa.

Other adult health in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →